1. Home
  2. BLND vs MLYS Comparison

BLND vs MLYS Comparison

Compare BLND & MLYS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Blend Labs Inc.

BLND

Blend Labs Inc.

HOLD

Current Price

$3.18

Market Cap

894.7M

Sector

Technology

ML Signal

HOLD

Logo Mineralys Therapeutics Inc.

MLYS

Mineralys Therapeutics Inc.

HOLD

Current Price

$36.99

Market Cap

3.1B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
BLND
MLYS
Founded
2012
2019
Country
United States
United States
Employees
N/A
N/A
Industry
EDP Services
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
894.7M
3.1B
IPO Year
2021
2023

Fundamental Metrics

Financial Performance
Metric
BLND
MLYS
Price
$3.18
$36.99
Analyst Decision
Buy
Strong Buy
Analyst Count
6
6
Target Price
$4.80
$46.40
AVG Volume (30 Days)
4.0M
1.6M
Earning Date
11-06-2025
11-10-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$167,532,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$19.81
N/A
P/E Ratio
N/A
N/A
Revenue Growth
37.61
N/A
52 Week Low
$2.50
$8.24
52 Week High
$5.34
$47.65

Technical Indicators

Market Signals
Indicator
BLND
MLYS
Relative Strength Index (RSI) 49.24 40.09
Support Level $3.18 $35.77
Resistance Level $3.40 $44.13
Average True Range (ATR) 0.14 1.93
MACD 0.03 -0.64
Stochastic Oscillator 48.89 14.95

Price Performance

Historical Comparison
BLND
MLYS

About BLND Blend Labs Inc.

Blend Labs Inc is a cloud-based platform software platform that powers the digital interface between financial services firms and consumers. It supports and simplifies applications for mortgages, consumer loans, and deposit accounts. Its operating segments are; Blend Platform segment which comprises a suite of products that power the entire origination process from back-end workflows to consumer experience, and the Title segment enables customers to streamline the title, settlement, and closing process at scale for mortgages, home equity lines of credit, and home equity loans. The majority of the revenue for the company is generated from the Blend Platform segment.

About MLYS Mineralys Therapeutics Inc.

Mineralys Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing medicines to target diseases driven by abnormally elevated aldosterone. The company's product candidate, lorundrostat, is a proprietary, orally administered, selective aldosterone synthase inhibitor, that is initially developed for the treatment of patients with uncontrolled hypertension, defined as individuals who are unable to achieve BP of below 130/80 mmHg despite taking two or more lines of antihypertensive medication or resistant hypertension, typically including a diuretic.

Share on Social Networks: